Tags

Type your tag names separated by a space and hit enter

Multipotent mesenchymal stromal cells for autoimmune diseases: teaching new dogs old tricks.
Bone Marrow Transplant. 2009 Jun; 43(11):821-8.BM

Abstract

MSCs, otherwise known as multipotent mesenchymal stromal cells, are being examined for the treatment of autoimmune disease (AD) on the basis of their in vitro antiproliferative properties, efficacy in animal models, apparent low acute toxicity and the early positive anecdotal outcomes in human acute GVHD. Phase I/II clinical trials are underway in Crohn's disease and multiple sclerosis (MS) and are being planned for systemic lupus erythematosus (SLE), systemic sclerosis (SSc), systemic vasculitis and other AD. Open issues include patient selection, disease stage and activity, MSC source and expansion and long-term safety. Multidisciplinary groups are collaborating to ensure maximal use of available resources to establish the place, if any, of MSC in the treatment of AD.

Authors+Show Affiliations

Department of Rheumatology, University of Basel, University Rheumatology Clinic, Basel, Switzerland. alan.tyndall@fps-basel.chNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

19308035

Citation

Tyndall, A, and A Uccelli. "Multipotent Mesenchymal Stromal Cells for Autoimmune Diseases: Teaching New Dogs Old Tricks." Bone Marrow Transplantation, vol. 43, no. 11, 2009, pp. 821-8.
Tyndall A, Uccelli A. Multipotent mesenchymal stromal cells for autoimmune diseases: teaching new dogs old tricks. Bone Marrow Transplant. 2009;43(11):821-8.
Tyndall, A., & Uccelli, A. (2009). Multipotent mesenchymal stromal cells for autoimmune diseases: teaching new dogs old tricks. Bone Marrow Transplantation, 43(11), 821-8. https://doi.org/10.1038/bmt.2009.63
Tyndall A, Uccelli A. Multipotent Mesenchymal Stromal Cells for Autoimmune Diseases: Teaching New Dogs Old Tricks. Bone Marrow Transplant. 2009;43(11):821-8. PubMed PMID: 19308035.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Multipotent mesenchymal stromal cells for autoimmune diseases: teaching new dogs old tricks. AU - Tyndall,A, AU - Uccelli,A, Y1 - 2009/03/23/ PY - 2009/3/25/entrez PY - 2009/3/25/pubmed PY - 2009/11/10/medline SP - 821 EP - 8 JF - Bone marrow transplantation JO - Bone Marrow Transplant. VL - 43 IS - 11 N2 - MSCs, otherwise known as multipotent mesenchymal stromal cells, are being examined for the treatment of autoimmune disease (AD) on the basis of their in vitro antiproliferative properties, efficacy in animal models, apparent low acute toxicity and the early positive anecdotal outcomes in human acute GVHD. Phase I/II clinical trials are underway in Crohn's disease and multiple sclerosis (MS) and are being planned for systemic lupus erythematosus (SLE), systemic sclerosis (SSc), systemic vasculitis and other AD. Open issues include patient selection, disease stage and activity, MSC source and expansion and long-term safety. Multidisciplinary groups are collaborating to ensure maximal use of available resources to establish the place, if any, of MSC in the treatment of AD. SN - 1476-5365 UR - https://www.unboundmedicine.com/medline/citation/19308035/Multipotent_mesenchymal_stromal_cells_for_autoimmune_diseases:_teaching_new_dogs_old_tricks_ L2 - http://dx.doi.org/10.1038/bmt.2009.63 DB - PRIME DP - Unbound Medicine ER -